Today's Daily Dose brings you news about favorable results from Eisai/Biogen's phase II study of BAN2401 in Alzheimer's; MabVax' delisting from the Nasdaq; Regulus' workforce reduction; FDA approval of fully wristed, 60mm stapler and Zynerba pulling the plug on THC Prodrug ZYN001.
from RTT - Biotech https://ift.tt/2IXK23Z
via IFTTT
No comments:
Post a Comment